Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy
暂无分享,去创建一个
Alessandro Padovani | Marco Trabucchi | M. Trabucchi | A. Padovani | L. Rozzini | Luca Rozzini | Giuseppe Bellelli | G. Bellelli | B. Vicini Chilovi | Barbara Vicini Chilovi | Erik Bertoletti | E. Bertoletti
[1] M. Lawton,et al. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .
[2] Dirk Deleu,et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.
[3] T. Hemnani,et al. Alzheimer’s disease pathogenesis and therapeutic interventions , 2004, Journal of Clinical Neuroscience.
[4] H. Arai,et al. Angiotensin‐Converting Enzyme Inhibitors and Incidence of Alzheimer's Disease in Japan , 2004, Journal of the American Geriatrics Society.
[5] A. Routtenberg,et al. Angiotensin injected into the neostriatum after learning disrupts retention performance. , 1977, Science.
[6] J. O'Brien,et al. Drugs for Alzheimer's disease , 2001, BMJ : British Medical Journal.
[7] B. Lernfelt,et al. 15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.
[8] A. Hofman,et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.
[9] J. Noble,et al. Drugs for Alzheimer's disease , 2001, BMJ : British Medical Journal.
[10] E. Peskind,et al. Galantamine in AD , 2000, Neurology.
[11] Second Edition,et al. Statistical Package for the Social Sciences , 1970 .
[12] J. Staessen,et al. Dementia and antihypertensive treatment. , 2004, Current opinion in nephrology and hypertension.
[13] S. Katz,et al. Progress in development of the index of ADL. , 1970, The Gerontologist.
[14] L. Wilkins. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.
[15] P. Tariot,et al. A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting , 2001, Journal of the American Geriatrics Society.
[16] V. Kostic,et al. Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease. , 1997, The International journal of neuroscience.
[17] Jan A Staessen,et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.
[18] B. Costall,et al. Angiofensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease , 1991 .
[19] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[20] Jaakko Tuomilehto,et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .
[21] T. Erkinjuntti,et al. POTENTIAL LONG‐TERM EFFECTS OF RIVASTIGMINE ON DISEASE PROGRESSION MAY BE LINKED TO DRUG EFFECTS ON VASCULAR CHANGES IN ALZHEIMER BRAINS , 2003, International journal of clinical practice.
[22] R. Anand,et al. An efficacy and safety analysis of Exelon® in Alzheimer’s disease patients with concurrent vascular risk factors , 2000, European journal of neurology.
[23] C. Bulpitt,et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial , 2004, Journal of hypertension.
[24] M. Lawton,et al. Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.
[25] M. Farlow,et al. A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease , 2000, European Neurology.
[26] C. Hock,et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia , 2001, Neurobiology of Aging.
[27] F. Graeff,et al. Effect of intracerebroventricular bradykinin and related peptides on rabbit operant behavior. , 1975, Journal of Pharmacology and Experimental Therapeutics.
[28] T. Crook,et al. Angiotensin converting enzyme and memory: preclinical and clinical data. , 1987, International journal of neurology.
[29] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[30] P. Ghisdal,et al. Intraneuronal amyloid‐β1‐42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death , 2004, Journal of neurochemistry.
[31] N. Hirawa,et al. Long-term inhibition of renin-angiotensin system sustains memory function in aged Dahl rats. , 1999, Hypertension.
[32] R. Doody,et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study , 2000, European Neuropsychopharmacology.